Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Isolyser.

This article was originally published in The Gray Sheet

Executive Summary

Restructuring plan announced March 3 includes anticipated divestiture of two base materials manufacturing plants as well as the firm's White Knight pack and gown product subsidiary. Norcross, Georgia-based Isolyser, which acquired White Knight in September 1995 for roughly $30 mil. ("The Gray Sheet" Aug. 21, 1995, p. 26), notes the plan is focused on continued development of Isolyser's Orex polymer technology and "reducing debt and achieving profitability." Revenues for 1997 declined 3% to $159.9 mil. A net loss of $93.9 mil. for the year compares to a loss of $20.5 mil. in 1996 and includes 1997 charges of $62 mil. related to asset impairment to the materials manufacturing plants and White Knight subsidiary, computer system installations, "and other charges," the firm states...

You may also be interested in...



GT Medical Technologies Raised $16M In Funding To Expand Brain Tumor Therapy

The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.

AMS Acquires Raleigh Adhesive Coatings Company For £22M ($29M) In Cash

Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business. 

Amgen Hands Omecamtiv Back To Cytokinetics

While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel